<bill session="117" type="s" number="4349" updated="2022-12-29T17:33:53Z">
  <state datetime="2022-06-06">REFERRED</state>
  <status>
    <introduced datetime="2022-06-06"/>
  </status>
  <introduced datetime="2022-06-06"/>
  <titles>
    <title type="display">A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to notifications of emerging signals concerning devices.</title>
    <title type="official" as="introduced">A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to notifications of emerging signals concerning devices.</title>
  </titles>
  <sponsor bioguide_id="M001198"/>
  <cosponsors>
    <cosponsor bioguide_id="B001310" joined="2022-06-06"/>
  </cosponsors>
  <actions>
    <action datetime="2022-06-06">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2022-06-06" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="h" number="7646" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2022-10-21T20:33:46Z" status="Introduced in Senate">This bill establishes certain requirements relating to the Food and Drug Administration's (FDA's) public notices on the potential new risks of approved medical devices (i.e., emerging signals), including with respect to the standards of evidence needed for such notices. The FDA must update its current guidance on emerging signals to align with the bill's requirements.</summary>
</bill>
